Altiti, Ahmad
He, Mingzhu http://orcid.org/0000-0001-7779-2411
VanPatten, Sonya http://orcid.org/0000-0001-9304-4579
Cheng, Kai Fan
Ahmed, Umair http://orcid.org/0000-0003-1991-1069
Chiu, Pui Yan
Mughrabi, Ibrahim T.
Jabari, Bayan Al
Burch, Ronald M.
Manogue, Kirk R.
Tracey, Kevin J. http://orcid.org/0000-0003-1884-6314
Diamond, Betty http://orcid.org/0000-0002-3250-3804
Metz, Christine N.
Yang, Huan
Hudson, LaQueta K.
Zanos, Stavros http://orcid.org/0000-0002-3967-8164
Son, Myoungsun http://orcid.org/0000-0002-0655-3859
Sherry, Barbara http://orcid.org/0000-0003-3119-1463
Coleman, Thomas R.
Al-Abed, Yousef http://orcid.org/0000-0001-5478-0506
Article History
Received: 9 November 2021
Accepted: 3 November 2022
First Online: 28 November 2022
Competing interests
: A.A., Y.A. are on a patent application held by the Feinstein Institutes for Medical Research (FIMR) related to the azapeptide synthesis platform- Preparation of acyl thiols including thiosemicarbazates and their use in the synthesis of peptides and peptidomiometics WO2020227592 A1 2020-11-12 (active). Y.A. is inventor (FIMR) on Synthesis and uses of peptidomimetics including azapeptides, WO2020227588 A1 2020-11-12 (active). Y.A., H.Y., K.J.T. are inventors on patents related to HMGB1 antagonists, including FSSE and corresponding azapeptide derivatives held by FIMR. Specifically, for H.Y., Y.A.-Composition of HMGB1 antagonist tetramer and therapeutic uses thereof, WO2020227603 A1 2020-11-12 (active)., and for K.J.T., H.Y., Y.A. -Treatment of HMGB1-mediated inflammation by administering an MD2-antagonist, WO2016094899 A2 2016-06-16 (active), and -Treatment of hmgb1-mediated inflammation, WO2016094899 A2 2015-12-14 (active). All other authors declare no competing interests.